#obesity-medications

[ follow ]
#prescription-drug-pricing #direct-to-consumer #trump-administration #glp-1-receptor-agonists
fromABC7 Los Angeles
3 weeks ago

TrumpRx launches, but it's unclear if it will lower drug prices for most patients

TrumpRx, the Trump administration's much-anticipated direct-to-consumer drug platform, went live on Thursday. A key pillar of President Donald Trump's effort to lower prescription drug costs, the website will serve as a clearinghouse that connects patients with drugmakers selling certain products to those willing to pay cash and forgo insurance. The medications, including the blockbuster obesity drugs Zepbound and Wegovy, will be available at a discount through these channels.
US politics
fromFast Company
3 months ago

Trump unveils deal with Eli Lilly and Novo Nordisk to lower costs and expand coverage for obesity drugs

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy. The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years. But access to the drugs has been a consistent problem for patients because of their cost - around $500 a month for higher doses - and insurance coverage has been spotty.
US politics
Healthcare
fromFast Company
7 months ago

Wegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challenge

Prices for Wegovy and Zepbound are decreasing, but access remains hindered by high costs and uneven insurance coverage.
[ Load more ]